Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
200 shown of 2,661 total abstracts
  1. Abstract 90112026-09-03 · 20:30 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-408 study)
    M. Reck, T. Mok, C. Saura, et al. · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  2. Abstract 46022026-09-02 · 14:45 CT · Arie Crown Theater
    Real-world effectiveness of Padcev vs standard of care in urothelial carcinoma
    G. Curigliano, S. Modi, F. Andre · Chinese University of Hong Kong
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  3. Abstract 41182026-09-03 · 16:45 CT · Arie Crown Theater
    DESTINY-Breast-378: Enhertu (trastuzumab deruxtecan) 3L+ in gastric
    H. Rugo, H. Borghaei, E. Winer, et al. · Massachusetts General Hospital
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  4. Abstract 60602026-09-05 · 14:45 CT · E450
    Quality of life outcomes with Lynparza in patients with ovarian
    C. Robert, L. Paz-Ares, C. Saura, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  5. Abstract 11592026-09-03 · 18:15 CT · S406
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-785
    F. Andre, C. Saura · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  6. Abstract 16772026-09-04 · 20:30 CT · E450
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    J. Cortes, M.C. Garassino, A. Spira, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  7. Abstract 98992026-09-02 · 19:00 CT · S406
    Long-term follow-up of Tecentriq adjuvant for NSCLC: IMpower-682
    J. Cortes, R. Herbst · Institut Gustave Roussy
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  8. Abstract 94702026-09-02 · 14:00 CT · Arie Crown Theater
    PACIFIC-166: Imfinzi (durvalumab) 2L in SCLC
    S. Peters, A. Spira, E. Winer, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  9. Abstract 97102026-09-03 · 19:15 CT · S406
    Long-term follow-up of Keytruda neoadjuvant for metastatic melanoma: KEYNOTE-221
    F. Andre, C. Robert, T. Mok · MD Anderson Cancer Center
    Oral Abstract SessionMelanoma📄🖼️🎬
  10. Abstract 16112026-09-03 · 18:30 CT · S100A
    MONARCH-55: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    P. Schmid, S. Tolaney, S. Modi, et al. · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  11. Abstract 94092026-09-02 · 13:45 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with NSCLC
    T. Mok, C. Saura · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  12. Abstract 43612026-09-05 · 13:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-691 study)
    H. Borghaei, R. Herbst · Chinese University of Hong Kong
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  13. Abstract 18772026-09-01 · 20:00 CT · Hall B1
    Long-term follow-up of Lynparza 3L+ for HR+ breast cancer: OlympiA-794
    S. Peters, J. Cortes, S. Modi · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  14. Abstract 97422026-09-04 · 20:30 CT · E450
    Long-term follow-up of Opdivo 1L for metastatic melanoma: CheckMate-99
    S. Modi, T. Mok, P. Schmid, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionMelanoma📄🖼️🎬
  15. Abstract 98482026-09-01 · 21:30 CT · E450
    Real-world effectiveness of Keytruda vs standard of care in metastatic melanoma
    H. Borghaei, C. Robert, N. Rizvi, et al. · Mayo Clinic
    Oral Abstract SessionMelanoma📄🖼️🎬
  16. Abstract 15342026-09-05 · 20:30 CT · S100A
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    A. Spira, M.C. Garassino, J. Cortes, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  17. Abstract 46702026-09-02 · 19:45 CT · S100A
    Quality of life outcomes with Trodelvy in patients with urothelial carcinoma
    J. Cortes, S. Tolaney, A. Spira · Chinese University of Hong Kong
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  18. Abstract 16082026-09-02 · 18:45 CT · E450
    MONARCH-69: Verzenio (abemaciclib) 1L in HR+ breast cancer
    H. Rugo, M. Krop, M.C. Garassino · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  19. Abstract 96192026-09-05 · 16:15 CT · E450
    CheckMate-196: Opdivo (nivolumab) 3L+ in NSCLC
    L. Paz-Ares, G. Curigliano, C. Robert, et al. · Stanford Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  20. Abstract 12282026-09-04 · 21:00 CT · E450
    MONALEESA-283: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    F. Andre, L. Paz-Ares · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  21. Abstract 91622026-09-03 · 20:15 CT · S100A
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-167 study)
    T. Mok, M. Reck, M.C. Garassino, et al. · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  22. Abstract 46032026-09-02 · 16:45 CT · S406
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-710 study)
    J. Cortes, T. Mok, M. Reck, et al. · Royal Marsden Hospital
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  23. Abstract 16662026-09-05 · 13:15 CT · Arie Crown Theater
    Quality of life outcomes with Trodelvy in patients with TNBC
    G. Curigliano, M. Krop, L. Paz-Ares · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  24. Abstract 17722026-09-05 · 20:00 CT · Hall B1
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-8
    M.C. Garassino, T. Mok · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  25. Abstract 69382026-09-02 · 15:45 CT · Arie Crown Theater
    Long-term follow-up of Opdivo maintenance for RCC: CheckMate-231
    J. Brahmer, P. Schmid, C. Saura · MD Anderson Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  26. Abstract 19452026-09-02 · 14:30 CT · S100A
    ASCENT-826: Trodelvy (sacituzumab govitecan) 3L+ in TNBC
    J. Cortes, R. Herbst, S. Tolaney, et al. · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  27. Abstract 101112026-09-02 · 14:00 CT · S100A
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-700 study)
    L. Paz-Ares, N. Rizvi, P. Schmid · Cleveland Clinic
    Oral Abstract SessionMelanoma📄🖼️🎬
  28. Abstract 45702026-09-02 · 21:45 CT · E450
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-684
    S. Peters, M. Krop, M.C. Garassino · Massachusetts General Hospital
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  29. Abstract 12902026-09-01 · 20:00 CT · Hall B1
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    J. Cortes, S. Antonia · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  30. Abstract 90642026-09-05 · 21:15 CT · Hall B1
    KEYNOTE-757: Keytruda (pembrolizumab) neoadjuvant in SCLC
    M. Krop, L. Paz-Ares, C. Saura, et al. · Mayo Clinic
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  31. Abstract 19792026-09-01 · 13:45 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-231
    P. Schmid, H. Rugo · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  32. Abstract 44962026-09-02 · 13:15 CT · S406
    Long-term follow-up of Padcev 1L for urothelial carcinoma: EV-513
    R. Herbst, C. Robert, G. Curigliano, et al. · Cleveland Clinic
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  33. Abstract 19142026-09-04 · 21:45 CT · E450
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    G. Curigliano, P. Schmid · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  34. Abstract 18532026-09-03 · 13:15 CT · Hall B1
    Long-term follow-up of Verzenio adjuvant for HR+ breast cancer: MONARCH-797
    H. Rugo, N. Rizvi, H. Borghaei · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  35. Abstract 14172026-09-02 · 15:15 CT · E450
    PALOMA-983: Ibrance (palbociclib) 2L in HR+ breast cancer
    R. Herbst, L. Paz-Ares, A. Spira, et al. · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  36. Abstract 42672026-09-01 · 18:15 CT · Hall B1
    Real-world effectiveness of Trodelvy vs standard of care in urothelial carcinoma
    S. Tolaney, S. Peters, N. Rizvi, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  37. Abstract 99802026-09-04 · 15:15 CT · S100A
    Quality of life outcomes with Tagrisso in patients with NSCLC
    M.C. Garassino, T. Mok, L. Paz-Ares · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  38. Abstract 14532026-09-05 · 15:45 CT · S406
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-645
    M. Reck, S. Tolaney, L. Paz-Ares · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  39. Abstract 90702026-09-05 · 21:45 CT · Hall B1
    FLAURA-771: Tagrisso (osimertinib) 1L in NSCLC
    E. Winer, S. Peters, S. Modi, et al. · National Cancer Center Japan
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  40. Abstract 45082026-09-02 · 16:00 CT · Hall B1
    EV-289: Padcev (enfortumab vedotin) adjuvant in urothelial carcinoma
    H. Rugo, F. Andre, M. Reck, et al. · Stanford Cancer Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  41. Abstract 12402026-09-01 · 18:15 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-382
    F. Andre, J. Brahmer · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  42. Abstract 45222026-09-03 · 20:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in HCC (the CheckMate-629 study)
    N. Rizvi, M. Krop, F. Andre · Mayo Clinic
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  43. Abstract 47022026-09-03 · 20:00 CT · Hall B1
    ASCENT-504: Trodelvy (sacituzumab govitecan) adjuvant in urothelial carcinoma
    P. Schmid, S. Tolaney, M. Krop, et al. · Cleveland Clinic
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  44. Abstract 63312026-09-01 · 15:15 CT · S406
    KEYNOTE-757: Keytruda (pembrolizumab) neoadjuvant in RCC
    A. Spira, S. Tolaney, E. Winer, et al. · Stanford Cancer Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  45. Abstract 11142026-09-03 · 21:45 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-236 study)
    C. Saura, L. Paz-Ares · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  46. Abstract 10732026-09-01 · 15:15 CT · Arie Crown Theater
    Long-term follow-up of Trodelvy adjuvant for TNBC: ASCENT-321
    M. Krop, A. Spira, J. Brahmer, et al. · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  47. Abstract 54072026-09-04 · 14:15 CT · S100A
    Quality of life outcomes with Lynparza in patients with prostate
    A. Spira, P. Schmid, M.C. Garassino · MD Anderson Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  48. Abstract 43142026-09-02 · 20:15 CT · S406
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-325
    S. Modi, S. Tolaney, L. Paz-Ares, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  49. Abstract 90212026-09-05 · 13:30 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-783
    A. Spira, S. Modi, C. Saura · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  50. Abstract 10902026-09-04 · 15:15 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-753
    J. Brahmer, H. Rugo, C. Robert · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  51. Abstract 10482026-09-03 · 19:30 CT · S406
    Long-term follow-up of Enhertu adjuvant for HR+ breast cancer: DESTINY-Breast-318
    L. Paz-Ares, J. Cortes · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  52. Abstract 16602026-09-03 · 13:45 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-232 study)
    M. Reck, S. Peters · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  53. Abstract 56822026-09-05 · 19:00 CT · Arie Crown Theater
    Long-term follow-up of Lynparza 1L for prostate: OlympiA-465
    G. Curigliano, E. Winer, M.C. Garassino · Stanford Cancer Institute
    Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  54. Abstract 46072026-09-03 · 16:00 CT · Arie Crown Theater
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-782
    S. Tolaney, J. Brahmer, L. Paz-Ares · Massachusetts General Hospital
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  55. Abstract 17522026-09-05 · 16:15 CT · S100A
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-449
    C. Robert, M. Reck, N. Rizvi, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  56. Abstract 91152026-09-02 · 13:15 CT · S406
    Real-world effectiveness of Opdivo vs standard of care in NSCLC
    T. Mok, E. Winer, G. Curigliano, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  57. Abstract 16052026-09-01 · 18:15 CT · Arie Crown Theater
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    P. Schmid, M. Krop, F. Andre, et al. · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  58. Abstract 52322026-09-03 · 14:00 CT · E450
    Real-world effectiveness of Lynparza vs standard of care in prostate
    A. Spira, R. Herbst, J. Brahmer, et al. · National Cancer Center Japan
    Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  59. Abstract 99662026-09-04 · 13:15 CT · S100A
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-223
    G. Curigliano, S. Peters, A. Spira, et al. · Stanford Cancer Institute
    Oral Abstract SessionMelanoma📄🖼️🎬
  60. Abstract 69952026-09-05 · 16:00 CT · S406
    Quality of life outcomes with Opdivo in patients with RCC
    G. Curigliano, P. Schmid, H. Rugo, et al. · Cleveland Clinic
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  61. Abstract 11942026-09-04 · 13:45 CT · Hall B1
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    E. Winer, P. Schmid, J. Cortes, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  62. Abstract 42212026-09-01 · 18:45 CT · Arie Crown Theater
    Real-world effectiveness of Enhertu vs standard of care in gastric
    T. Mok, N. Rizvi, S. Tolaney, et al. · MD Anderson Cancer Center
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  63. Abstract 61452026-09-01 · 19:30 CT · S406
    Real-world effectiveness of Keytruda vs standard of care in RCC
    F. Andre, S. Tolaney · Peter MacCallum Cancer Centre
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  64. Abstract 18592026-09-02 · 15:15 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-587
    S. Antonia, H. Borghaei · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  65. Abstract 10422026-09-03 · 21:30 CT · S406
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    M. Reck, L. Paz-Ares, H. Borghaei · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  66. Abstract 44672026-09-04 · 18:30 CT · S406
    Quality of life outcomes with Tecentriq in patients with HCC
    C. Saura, J. Brahmer, R. Herbst · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  67. Abstract 10442026-09-03 · 18:30 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-708
    P. Schmid, M. Reck, M. Krop, et al. · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  68. Abstract 13012026-09-04 · 15:45 CT · S100A
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-619
    G. Curigliano, C. Saura, M. Reck, et al. · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  69. Abstract 40302026-09-03 · 20:15 CT · E450
    Long-term follow-up of Tecentriq 1L for HCC: IMpower-940
    R. Herbst, G. Curigliano · MD Anderson Cancer Center
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  70. Abstract 93522026-09-02 · 19:00 CT · S406
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-963
    L. Paz-Ares, S. Peters, S. Modi, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  71. Abstract 43772026-09-01 · 19:45 CT · E450
    Long-term follow-up of Tecentriq maintenance for HCC: IMpower-234
    S. Tolaney, S. Antonia, S. Modi · MD Anderson Cancer Center
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  72. Abstract 15482026-09-01 · 14:15 CT · Hall B1
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-433
    S. Antonia, L. Paz-Ares, M. Krop, et al. · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  73. Abstract 96662026-09-04 · 18:45 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-371
    M. Reck, A. Spira, S. Peters, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  74. Abstract 101992026-09-05 · 21:15 CT · Arie Crown Theater
    Quality of life outcomes with Opdivo in patients with metastatic melanoma
    R. Herbst, T. Mok, H. Borghaei, et al. · Cleveland Clinic
    Oral Abstract SessionMelanoma📄🖼️🎬
  75. Abstract 51742026-09-03 · 19:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Lynparza in prostate (the OlympiA-473 study)
    R. Herbst, S. Tolaney, J. Cortes, et al. · Massachusetts General Hospital
    Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  76. Abstract 62232026-09-02 · 18:45 CT · Hall B1
    Long-term follow-up of Opdivo neoadjuvant for RCC: CheckMate-378
    L. Paz-Ares, N. Rizvi, A. Spira · Royal Marsden Hospital
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  77. Abstract 67912026-09-05 · 18:45 CT · Hall B1
    Long-term follow-up of Keytruda 1L for RCC: KEYNOTE-952
    M.C. Garassino, R. Herbst, N. Rizvi, et al. · Massachusetts General Hospital
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  78. Abstract 18792026-09-01 · 20:45 CT · Arie Crown Theater
    Long-term follow-up of Lynparza 3L+ for HR+ breast cancer: OlympiA-960
    M. Krop, S. Peters, M.C. Garassino, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  79. Abstract 66962026-09-02 · 19:00 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-434 study)
    L. Paz-Ares, C. Robert, R. Herbst, et al. · Massachusetts General Hospital
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  80. Abstract 10732026-09-03 · 13:45 CT · S406
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-41
    S. Peters, S. Tolaney, G. Curigliano, et al. · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  81. Abstract 43482026-09-02 · 20:30 CT · Arie Crown Theater
    ASCENT-210: Trodelvy (sacituzumab govitecan) 3L+ in urothelial carcinoma
    M. Reck, S. Antonia, S. Peters · Dana-Farber Cancer Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  82. Abstract 62712026-09-04 · 18:45 CT · E450
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-705
    M. Krop, C. Saura · Stanford Cancer Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  83. Abstract 99932026-09-02 · 15:15 CT · E450
    Long-term follow-up of Opdivo maintenance for NSCLC: CheckMate-999
    H. Rugo, C. Saura, S. Tolaney, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  84. Abstract 13072026-09-01 · 14:45 CT · Arie Crown Theater
    DESTINY-Breast-18: Enhertu (trastuzumab deruxtecan) maintenance in HR+ breast cancer
    E. Winer, R. Herbst · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  85. Abstract 93762026-09-02 · 21:00 CT · S100A
    Long-term follow-up of Imfinzi neoadjuvant for NSCLC: PACIFIC-872
    E. Winer, F. Andre, S. Peters, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  86. Abstract 65882026-09-03 · 18:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-213 study)
    M. Reck, J. Brahmer · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  87. Abstract 43082026-09-03 · 14:30 CT · Arie Crown Theater
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-756
    J. Cortes, C. Saura, F. Andre · National Cancer Center Japan
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  88. Abstract 12542026-09-04 · 18:30 CT · S100A
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-846 study)
    A. Spira, T. Mok, H. Rugo, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  89. Abstract 42552026-09-01 · 14:00 CT · E450
    Quality of life outcomes with Padcev in patients with urothelial carcinoma
    E. Winer, F. Andre, P. Schmid · National Cancer Center Japan
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  90. Abstract 40452026-09-05 · 15:00 CT · S406
    ASCENT-510: Trodelvy (sacituzumab govitecan) 3L+ in urothelial carcinoma
    S. Peters, J. Brahmer, C. Robert, et al. · National Cancer Center Japan
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  91. Abstract 97282026-09-02 · 16:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-5 study)
    M.C. Garassino, F. Andre, T. Mok · Chinese University of Hong Kong
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  92. Abstract 45752026-09-05 · 18:30 CT · S406
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-493 study)
    M.C. Garassino, L. Paz-Ares, J. Brahmer · Stanford Cancer Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  93. Abstract 90132026-09-03 · 13:45 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-59
    L. Paz-Ares, F. Andre, S. Tolaney, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  94. Abstract 100052026-09-04 · 14:15 CT · S100A
    CheckMate-390: Opdivo (nivolumab) 3L+ in metastatic melanoma
    H. Borghaei, S. Tolaney · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionMelanoma📄🖼️🎬
  95. Abstract 10652026-09-05 · 21:30 CT · S100A
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    L. Paz-Ares, J. Cortes, H. Rugo, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  96. Abstract 13492026-09-04 · 16:00 CT · E450
    MONARCH-322: Verzenio (abemaciclib) adjuvant in HR+ breast cancer
    S. Tolaney, E. Winer, J. Brahmer · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  97. Abstract 97962026-09-03 · 20:30 CT · S406
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-273 study)
    S. Peters, S. Tolaney · University of Chicago
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  98. Abstract 49452026-09-01 · 20:30 CT · Arie Crown Theater
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-91
    F. Andre, R. Herbst, C. Robert, et al. · Karolinska Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  99. Abstract 90242026-09-04 · 16:00 CT · S100A
    Quality of life outcomes with Tecentriq in patients with NSCLC
    M. Krop, H. Borghaei, S. Modi, et al. · National Cancer Center Japan
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  100. Abstract 18922026-09-02 · 13:00 CT · E450
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-385
    J. Brahmer, S. Antonia, C. Saura · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  101. Abstract 15402026-09-01 · 14:30 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-954 study)
    N. Rizvi, S. Tolaney, J. Brahmer, et al. · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  102. Abstract 17992026-09-03 · 20:30 CT · E450
    Long-term follow-up of Lynparza maintenance for HR+ breast cancer: OlympiA-48
    S. Antonia, T. Mok, M. Krop, et al. · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  103. Abstract 14062026-09-05 · 19:15 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-648
    S. Modi, S. Tolaney, L. Paz-Ares, et al. · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  104. Abstract 49762026-09-03 · 21:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Imfinzi in biliary tract (the PACIFIC-376 study)
    C. Saura, M.C. Garassino, J. Brahmer, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  105. Abstract 95752026-09-03 · 19:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-306 study)
    S. Antonia, M. Reck · National Cancer Center Japan
    Oral Abstract SessionMelanoma📄🖼️🎬
  106. Abstract 15902026-09-01 · 15:45 CT · Arie Crown Theater
    Long-term follow-up of Verzenio adjuvant for HR+ breast cancer: MONARCH-509
    L. Paz-Ares, J. Brahmer · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  107. Abstract 49982026-09-04 · 18:45 CT · Hall B1
    Long-term follow-up of Padcev neoadjuvant for urothelial carcinoma: EV-562
    S. Tolaney, J. Brahmer · Karolinska Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  108. Abstract 56002026-09-02 · 13:30 CT · Hall B1
    Long-term follow-up of Lynparza neoadjuvant for ovarian: OlympiA-623
    H. Borghaei, N. Rizvi, E. Winer, et al. · Institut Gustave Roussy
    Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  109. Abstract 16132026-09-05 · 13:15 CT · E450
    Long-term follow-up of Tecentriq 1L for TNBC: IMpower-638
    L. Paz-Ares, M. Krop, R. Herbst, et al. · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  110. Abstract 40602026-09-02 · 16:15 CT · Hall B1
    Long-term follow-up of Padcev maintenance for urothelial carcinoma: EV-556
    S. Tolaney, S. Peters, S. Antonia, et al. · Cleveland Clinic
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  111. Abstract 93372026-09-04 · 14:15 CT · Hall B1
    Long-term follow-up of Tecentriq 1L for NSCLC: IMpower-160
    M.C. Garassino, R. Herbst, C. Saura · Chinese University of Hong Kong
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  112. Abstract 43742026-09-03 · 15:15 CT · S100A
    Long-term follow-up of Imfinzi adjuvant for biliary tract: PACIFIC-532
    C. Saura, C. Robert · Royal Marsden Hospital
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  113. Abstract 10062026-09-03 · 21:30 CT · S100A
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-864
    S. Tolaney, N. Rizvi, C. Robert, et al. · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  114. Abstract 44562026-09-04 · 13:30 CT · E450
    ASCENT-895: Trodelvy (sacituzumab govitecan) 3L+ in urothelial carcinoma
    A. Spira, M. Reck, L. Paz-Ares, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  115. Abstract 14962026-09-05 · 18:00 CT · S100A
    DESTINY-Breast-813: Enhertu (trastuzumab deruxtecan) 2L in HR+ breast cancer
    S. Tolaney, M. Reck, S. Modi, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  116. Abstract 10662026-09-01 · 15:00 CT · E450
    KEYNOTE-299: Keytruda (pembrolizumab) neoadjuvant in TNBC
    C. Saura, T. Mok, S. Tolaney, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  117. Abstract 103192026-09-01 · 13:00 CT · S100A
    Long-term follow-up of Keytruda 3L+ for metastatic melanoma: KEYNOTE-945
    N. Rizvi, C. Robert, M. Reck, et al. · Stanford Cancer Institute
    Oral Abstract SessionMelanoma📄🖼️🎬
  118. Abstract 16382026-09-01 · 19:30 CT · S406
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-54
    T. Mok, A. Spira, H. Borghaei, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  119. Abstract 40482026-09-03 · 21:30 CT · S406
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-909
    R. Herbst, M. Krop · Institut Gustave Roussy
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  120. Abstract 13212026-09-01 · 19:00 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-418
    L. Paz-Ares, J. Brahmer · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  121. Abstract 14942026-09-04 · 21:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-99 study)
    R. Herbst, F. Andre, N. Rizvi, et al. · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  122. Abstract 12792026-09-04 · 20:15 CT · Hall B1
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-168 study)
    J. Brahmer, M.C. Garassino, E. Winer · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  123. Abstract 43212026-09-01 · 16:30 CT · E450
    EV-920: Padcev (enfortumab vedotin) 2L in urothelial carcinoma
    C. Robert, L. Paz-Ares · Chinese University of Hong Kong
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  124. Abstract 15692026-09-04 · 18:15 CT · S406
    MONALEESA-607: Kisqali (ribociclib) 2L in HR+ breast cancer
    M. Reck, H. Borghaei, T. Mok · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  125. Abstract 47402026-09-02 · 18:45 CT · E450
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-412
    M. Reck, P. Schmid, J. Cortes, et al. · Massachusetts General Hospital
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  126. Abstract 91812026-09-05 · 19:30 CT · Hall B1
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-631
    P. Schmid, E. Winer, H. Borghaei · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  127. Abstract 42572026-09-02 · 19:45 CT · E450
    Long-term follow-up of Padcev neoadjuvant for urothelial carcinoma: EV-938
    H. Borghaei, C. Robert · Stanford Cancer Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  128. Abstract 14992026-09-04 · 16:30 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-292
    R. Herbst, P. Schmid, M.C. Garassino, et al. · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  129. Abstract 96612026-09-02 · 14:00 CT · Arie Crown Theater
    PACIFIC-371: Imfinzi (durvalumab) neoadjuvant in SCLC
    M. Krop, S. Peters, T. Mok, et al. · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  130. Abstract 49662026-09-04 · 15:45 CT · E450
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-975 study)
    S. Tolaney, R. Herbst, M. Reck, et al. · National Cancer Center Japan
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  131. Abstract 94842026-09-04 · 13:30 CT · Hall B1
    KEYNOTE-25: Keytruda (pembrolizumab) adjuvant in SCLC
    G. Curigliano, H. Rugo, P. Schmid, et al. · National Cancer Center Japan
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  132. Abstract 12312026-09-04 · 21:15 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-146 study)
    M.C. Garassino, S. Peters, N. Rizvi, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  133. Abstract 93392026-09-03 · 16:30 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-153 study)
    R. Herbst, G. Curigliano, J. Brahmer, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  134. Abstract 12612026-09-02 · 14:30 CT · S100A
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    R. Herbst, J. Brahmer · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  135. Abstract 40612026-09-01 · 15:45 CT · Hall B1
    Long-term follow-up of Enhertu 1L for gastric: DESTINY-Breast-355
    R. Herbst, C. Saura, G. Curigliano, et al. · Royal Marsden Hospital
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  136. Abstract 41252026-09-01 · 14:30 CT · Hall B1
    ASCENT-517: Trodelvy (sacituzumab govitecan) 2L in urothelial carcinoma
    L. Paz-Ares, E. Winer, H. Rugo, et al. · Royal Marsden Hospital
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  137. Abstract 12802026-09-03 · 14:45 CT · S100A
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-121
    J. Brahmer, M. Reck, R. Herbst, et al. · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  138. Abstract 97372026-09-05 · 19:45 CT · S100A
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-493
    M.C. Garassino, T. Mok · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  139. Abstract 60962026-09-05 · 20:30 CT · Hall B1
    Biomarker subgroup analysis of Lynparza in ovarian (the OlympiA-703 study)
    S. Antonia, F. Andre, M. Reck, et al. · Chinese University of Hong Kong
    Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  140. Abstract 95512026-09-01 · 20:45 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-858
    N. Rizvi, M.C. Garassino, H. Rugo · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  141. Abstract 47442026-09-04 · 19:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Imfinzi in biliary tract (the PACIFIC-229 study)
    S. Antonia, J. Brahmer, G. Curigliano, et al. · Massachusetts General Hospital
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  142. Abstract 90412026-09-01 · 20:45 CT · E450
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-54
    E. Winer, J. Brahmer, C. Saura, et al. · Stanford Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  143. Abstract 14592026-09-04 · 15:30 CT · Hall B1
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-181
    M. Krop, C. Robert, S. Peters, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  144. Abstract 91002026-09-01 · 19:00 CT · S100A
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-964 study)
    N. Rizvi, A. Spira, J. Brahmer · Chinese University of Hong Kong
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  145. Abstract 18242026-09-03 · 19:30 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-662 study)
    M. Reck, C. Robert, H. Borghaei, et al. · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  146. Abstract 18702026-09-01 · 15:15 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-746 study)
    S. Tolaney, A. Spira, M. Reck, et al. · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  147. Abstract 99342026-09-03 · 13:30 CT · S406
    FLAURA-866: Tagrisso (osimertinib) 1L in NSCLC
    J. Cortes, H. Borghaei · Stanford Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  148. Abstract 18632026-09-01 · 20:30 CT · E450
    Long-term follow-up of Trodelvy adjuvant for TNBC: ASCENT-421
    P. Schmid, R. Herbst, N. Rizvi · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  149. Abstract 15002026-09-01 · 19:00 CT · Hall B1
    IMpower-331: Tecentriq (atezolizumab) maintenance in TNBC
    S. Modi, T. Mok, C. Robert · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  150. Abstract 93072026-09-01 · 18:15 CT · Arie Crown Theater
    Real-world effectiveness of Keytruda vs standard of care in SCLC
    C. Robert, E. Winer · Institut Gustave Roussy
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  151. Abstract 46162026-09-05 · 20:00 CT · Hall B1
    PACIFIC-783: Imfinzi (durvalumab) 3L+ in biliary tract
    M. Krop, J. Cortes, N. Rizvi, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  152. Abstract 97732026-09-02 · 20:45 CT · E450
    FLAURA-616: Tagrisso (osimertinib) neoadjuvant in NSCLC
    N. Rizvi, L. Paz-Ares, M. Reck · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  153. Abstract 43882026-09-05 · 13:00 CT · S100A
    Long-term follow-up of Trodelvy 3L+ for urothelial carcinoma: ASCENT-402
    H. Borghaei, S. Peters, R. Herbst · Dana-Farber Cancer Institute
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  154. Abstract 12442026-09-04 · 19:30 CT · S406
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-623
    C. Robert, C. Saura · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  155. Abstract 15002026-09-01 · 21:15 CT · S100A
    MONALEESA-920: Kisqali (ribociclib) 2L in HR+ breast cancer
    R. Herbst, S. Modi · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  156. Abstract 14372026-09-01 · 19:00 CT · S406
    PALOMA-542: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    J. Brahmer, F. Andre, A. Spira, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  157. Abstract 44442026-09-02 · 15:45 CT · Arie Crown Theater
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-927
    J. Cortes, C. Saura, H. Rugo, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  158. Abstract 18352026-09-02 · 19:15 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-870 study)
    P. Schmid, G. Curigliano, M. Krop · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  159. Abstract 102482026-09-05 · 20:15 CT · S100A
    Long-term follow-up of Keytruda neoadjuvant for metastatic melanoma: KEYNOTE-253
    H. Rugo, J. Cortes, M. Reck, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionMelanoma📄🖼️🎬
  160. Abstract 60452026-09-04 · 14:30 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-82 study)
    G. Curigliano, J. Cortes, L. Paz-Ares · Mayo Clinic
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  161. Abstract 98762026-09-02 · 13:15 CT · Hall B1
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    L. Paz-Ares, P. Schmid, S. Peters, et al. · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  162. Abstract 45832026-09-01 · 19:00 CT · E450
    Quality of life outcomes with Enhertu in patients with gastric
    P. Schmid, E. Winer, M.C. Garassino, et al. · Cleveland Clinic
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  163. Abstract 91312026-09-04 · 13:15 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-648 study)
    S. Modi, M.C. Garassino, L. Paz-Ares, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  164. Abstract 98652026-09-01 · 20:30 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-586
    M. Krop, S. Peters, M.C. Garassino, et al. · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  165. Abstract 42262026-09-05 · 14:15 CT · E450
    Tecentriq plus chemotherapy in previously untreated HCC: updated analysis from IMpower-891
    M. Reck, C. Saura, G. Curigliano, et al. · MD Anderson Cancer Center
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  166. Abstract 60522026-09-01 · 19:15 CT · E450
    OlympiA-44: Lynparza (olaparib) 2L in ovarian
    J. Cortes, S. Antonia, N. Rizvi, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  167. Abstract 49102026-09-05 · 19:45 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-868 study)
    E. Winer, H. Borghaei, G. Curigliano · Institut Gustave Roussy
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  168. Abstract 18092026-09-04 · 19:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-157 study)
    M. Krop, S. Peters, F. Andre · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  169. Abstract 53332026-09-05 · 21:00 CT · S100A
    Biomarker subgroup analysis of Lynparza in prostate (the OlympiA-353 study)
    S. Tolaney, H. Borghaei, M. Reck · Mayo Clinic
    Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  170. Abstract 98242026-09-02 · 19:00 CT · S100A
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-485 study)
    G. Curigliano, C. Saura, N. Rizvi, et al. · National Cancer Center Japan
    Oral Abstract SessionMelanoma📄🖼️🎬
  171. Abstract 43172026-09-03 · 20:00 CT · Arie Crown Theater
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-960
    J. Brahmer, C. Robert · Peter MacCallum Cancer Centre
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  172. Abstract 54852026-09-02 · 18:45 CT · S100A
    Lynparza plus chemotherapy in previously untreated prostate: updated analysis from OlympiA-713
    M. Reck, S. Peters, H. Borghaei, et al. · Karolinska Institute
    Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  173. Abstract 59862026-09-02 · 21:15 CT · S406
    Lynparza plus chemotherapy in previously untreated ovarian: updated analysis from OlympiA-219
    E. Winer, S. Peters · Royal Marsden Hospital
    Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  174. Abstract 16522026-09-05 · 13:30 CT · E450
    Long-term follow-up of Keytruda 2L for TNBC: KEYNOTE-624
    N. Rizvi, L. Paz-Ares, H. Rugo, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  175. Abstract 97922026-09-01 · 20:45 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-519 study)
    H. Rugo, F. Andre · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  176. Abstract 40412026-09-01 · 21:30 CT · Arie Crown Theater
    Long-term follow-up of Enhertu maintenance for gastric: DESTINY-Breast-867
    J. Brahmer, S. Antonia · Chinese University of Hong Kong
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  177. Abstract 62582026-09-04 · 13:00 CT · S100A
    Real-world effectiveness of Lynparza vs standard of care in ovarian
    N. Rizvi, S. Modi, M.C. Garassino, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  178. Abstract 63452026-09-03 · 13:30 CT · E450
    OlympiA-336: Lynparza (olaparib) 2L in ovarian
    S. Modi, C. Saura · Dana-Farber Cancer Institute
    Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  179. Abstract 49172026-09-02 · 14:15 CT · S100A
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-143
    H. Rugo, C. Saura, G. Curigliano · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  180. Abstract 43042026-09-05 · 21:15 CT · Arie Crown Theater
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-379
    G. Curigliano, L. Paz-Ares · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  181. Abstract 46262026-09-02 · 13:30 CT · Hall B1
    DESTINY-Breast-378: Enhertu (trastuzumab deruxtecan) maintenance in gastric
    S. Modi, E. Winer, M.C. Garassino, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  182. Abstract 93262026-09-04 · 20:45 CT · S100A
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-940
    J. Brahmer, E. Winer · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  183. Abstract 68732026-09-04 · 15:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-524 study)
    M.C. Garassino, H. Borghaei · Institut Gustave Roussy
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  184. Abstract 19822026-09-02 · 19:30 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-743
    L. Paz-Ares, S. Antonia, S. Modi · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  185. Abstract 40452026-09-01 · 13:00 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated HCC: updated analysis from CheckMate-785
    H. Borghaei, L. Paz-Ares, T. Mok, et al. · Karolinska Institute
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  186. Abstract 45882026-09-02 · 15:15 CT · S100A
    Long-term follow-up of Tecentriq 2L for HCC: IMpower-35
    P. Schmid, M.C. Garassino, M. Krop · Stanford Cancer Institute
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  187. Abstract 48832026-09-03 · 14:45 CT · Arie Crown Theater
    Real-world effectiveness of Opdivo vs standard of care in HCC
    S. Modi, H. Borghaei, S. Tolaney, et al. · Stanford Cancer Institute
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  188. Abstract 49812026-09-04 · 18:45 CT · E450
    Real-world effectiveness of Imfinzi vs standard of care in biliary tract
    S. Peters, C. Robert, L. Paz-Ares, et al. · Karolinska Institute
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  189. Abstract 44362026-09-03 · 18:45 CT · E450
    Long-term follow-up of Padcev adjuvant for urothelial carcinoma: EV-343
    T. Mok, F. Andre, S. Peters · National Cancer Center Japan
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  190. Abstract 99232026-09-01 · 15:30 CT · Hall B1
    Real-world effectiveness of Opdivo vs standard of care in metastatic melanoma
    H. Borghaei, M.C. Garassino · Chinese University of Hong Kong
    Oral Abstract SessionMelanoma📄🖼️🎬
  191. Abstract 14042026-09-02 · 14:30 CT · S406
    OlympiA-199: Lynparza (olaparib) 2L in HR+ breast cancer
    H. Borghaei, S. Tolaney, M.C. Garassino, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  192. Abstract 17562026-09-01 · 16:45 CT · E450
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-382
    C. Robert, J. Brahmer, L. Paz-Ares, et al. · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  193. Abstract 19922026-09-02 · 14:30 CT · S100A
    MONALEESA-510: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    G. Curigliano, L. Paz-Ares, H. Borghaei, et al. · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  194. Abstract 95912026-09-05 · 14:30 CT · S100A
    CheckMate-447: Opdivo (nivolumab) 3L+ in NSCLC
    R. Herbst, M. Reck, S. Peters, et al. · Chinese University of Hong Kong
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  195. Abstract 42592026-09-02 · 16:00 CT · Hall B1
    PACIFIC-932: Imfinzi (durvalumab) maintenance in biliary tract
    S. Antonia, H. Rugo, G. Curigliano, et al. · Cleveland Clinic
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  196. Abstract 65052026-09-02 · 16:00 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-703
    N. Rizvi, G. Curigliano, S. Tolaney, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  197. Abstract 47812026-09-05 · 20:00 CT · S100A
    Quality of life outcomes with Imfinzi in patients with biliary tract
    C. Robert, H. Rugo, G. Curigliano, et al. · University of Chicago
    Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  198. Abstract 14722026-09-05 · 13:00 CT · Hall B1
    PALOMA-381: Ibrance (palbociclib) 1L in HR+ breast cancer
    T. Mok, G. Curigliano, S. Antonia, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  199. Abstract 93322026-09-03 · 20:00 CT · S406
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-529
    T. Mok, S. Peters, C. Robert, et al. · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  200. Abstract 10382026-09-02 · 16:45 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-322
    S. Modi, P. Schmid · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.